Genentech ranks among the world’s leading biotechnology companies, developing innovative therapies to address significant unmet medical needs. Launching the biotechnology industry with its founding in 1976, Genentech manufactures and commercializes multiple products for serious or life-threatening medical conditions in the fields of oncology, immunology, disorders of tissue growth and repair, neurobiology and infectious disease. The company currently has more than 100 projects in its pipeline. R&D expenditures were $2.4 billion in 2007, representing 21 percent of revenues. Research activities are conducted at its South San Francisco corporate headquarters. Genentech’s medical and scientific achievements include a history of “firsts” for patients. Among them are:

- the first human protein (somatostatin) produced in a microorganism
- the first recombinant DNA drug marketed (human insulin)
- the first laboratory production of Factor VIII, a clotting factor for bleeding in hemophiliacs
- the first recombinant DNA product manufactured and marketed by a biotechnology company, Protropin (somatrem for injection) growth hormone for children with growth hormone deficiency
• the first FDA-approved therapeutic antibody for cancer, Rituxan (Rituximab)
• the first FDA-approved therapeutic antibody targeted to a cancer-related molecular market, Herceptin (Trastuzumab)
• the first FDA-approved anti-angiogenic cancer therapy, Avastin (bevacizumab).

BIOGRAPHY

Arthur D. Levinson became chief executive officer of Genentech in July 1995. Dr. Levinson was appointed a member of the board of directors that same year and named chairman of the board in 1999.

Dr. Levinson joined the company in 1980 as a senior scientist and subsequently held the position of staff scientist and director of Cell Genetics at Genentech. He became vice president of Research Technology in 1989, vice president of Research in 1990, senior vice president of Research in 1992, and senior vice president of Research and Development in 1993. He has been a member of Genentech’s executive committee since 1990. Prior to his employment with Genentech, Levinson was a postdoctoral fellow in the department of microbiology at the University of California, San Francisco.

During his career, Dr. Levinson has served on the editorial boards of Molecular Biology and Medicine, Molecular and Cellular Biology, Journal of Virology, and Virology. He also served on the boards of the Pharmaceutical Research and Manufacturers of America, the Biotechnology Industry Organization, and the California Healthcare Institute. Dr. Levinson has authored or co-authored more than 80 scientific articles and has been a named inventor on 11 United States patents, including inventions in the research of production of recombinant proteins.

Dr. Levinson sits on the board of scientific consultants for the